Back to search results

THIO and Cadonilimab for Resectable Liver Cancer

This study is investigating if ateganosine and/or cadonilimab are safe and effective for treating resectable hepatocellular carcinoma (HCC), a type of liver cancer that can be surgically removed. You may be eligible if you are 18 or older, have HCC confirmed by a doctor, and your cancer can be completely removed by surgery. The study aims to see if these treatments delay surgery by more than 28 days. The study plans to enroll 60 participants, but its current status is unclear. You will be randomly assigned to receive cadonilimab alone, ateganosine alone, or both ateganosine and cadonilimab before your surgery.

Study design
This is an interventional study with 60 planned participants. You will be randomly assigned to one of three treatment groups.
What's involved
You will receive intravenous infusions of ateganosine and/or cadonilimab over several 21-day cycles before being evaluated for surgery.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured 28 days after your expected surgery date.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07446257

THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatment
University of Texas Southwestern Medical Center
~60 participants
Updated 2026-09-03 on ClinicalTrials.gov
What's tested:ateganosineCadonilimab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment-related delay of surgical resection >28 days from expected surgery date.
Measured over 28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms)

Conditions

Resectable Hepatocellular Carcinoma

Explore related trials

Hepatocellular Carcinoma

NCT07446257

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Texas Southwestern Medical Center

    Dallas, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Carrie Manwaring
[email protected]
214-648-7097
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has not undergone a hysterectomy or bilateral oophorectomy; or
Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). 11. Ability to understand and the willingness to sign a written informed consent. 12. Willing and able to comply with the requirements and restrictions in this protocol.

What this trial measures

  • Incidence of treatment-related delay of surgical resection >28 days from expected surgery date.28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms)

    Safety is measured as the proportion of participants who experience a treatment-related delay in the planned surgical resection, defined as surgery occurring more than 28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms)